Advanced topics in evidence-based urologic oncology: Surrogate endpoints

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 447-453

  Lavallée, Luke T ^a   Montori, Victor M ^b   Canfield, Stephen E ^c   Breau, Rodney H ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Biological Markers; Data Interpretation; Evidence based medicine; Surrogate endpoints

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; CANCER DIAGNOSIS; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL EFFECTIVENESS; DISEASE MARKER; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GLEASON SCORE; HOT FLUSH; HUMAN; INCONTINENCE; KIDNEY CARCINOMA; LIBIDO; MALE; METASTASIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT REFUSAL;

ANDROGEN ANTAGONISTS; BIOLOGICAL MARKERS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 79959860951     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.06.010     Document Type: Review

References (25)

1. Bucher H.C., Guyatt G.H., Cook D.J., et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999, 282:771-778.
2. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
3. Krupski T.L., Dahm P., Fesperman S.F., et al. How to perform a literature search. J Urol 2008, 179:1264-1270.
4. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
5. Ray M.E., Bae K., Hussain M.H., et al. Potential surrogate endpoints for prostate cancer survival: Analysis of a phase III randomized trial. J Natl Cancer Inst 2009, 101:228-236.
6. Guyatt G., Montori V., Devereaux P.J., et al. Patients at the center: In our practice, and in our use of language. ACP J Club 2004, 140:A11-A12.
7. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003, 21:2163-2172.
8. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
9. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
11. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
12. Taylor L.G., Canfield S.E., Du X.L. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115:2388-2399.
13. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99:1516-1524.
14. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
15. Collette L., Burzykowski T., Schroder F.H. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006, 42:1344-1350.
16. Moul J.W., Wu H., Sun L., et al. Early vs. delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141-1147.
17. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003, 95:1376-1383.
18. Vicini F.A., Vargas C., Abner A., et al. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005, 173:1456-1462.
19. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
20. Buyse M., Molenberghs G., Burzykowski T., et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000, 1:49-67.
21. Collette L., Burzykowski T., Carroll K.J., et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?. Joint research of the European Organization for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005, 23:6139-6148.
22. Prentice R.L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989, 8:431-440.
23. Swiglo B.A., Murad M.H., Schunemann H.J., et al. A case for clarity, consistency, and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008, 93:666-673.
24. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 2008, 54:816-823.
25. Breau R.H., Leibovich B.C. Therapy for metastatic RCC-questions remain. Nat Rev Urol 2009, 6:580-581.